Ideal candidates for semaglutide include: Adults with type 2 diabetes (Ozempic and Rybelsus) Adults who have established heart and blood vessel-related disease or those who are at risk of developing these diseases or heart failure (Ozempic) Adults with chronic kidney disease and type 2 diabetes, to reduce the risk of worsening kidney disease or end-stage renal disease (Ozempic) Children aged 12 or more, adolescents, and adults with obesity (BMI 30 or more) and overweight (BMI 27 or more) with at least one weight-related complication, such as hypercholesterolemia, hyperlipidemia, heart disease, and hypertension (Wegovy) Patients with metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring or fibrosis, but they should not have cirrhosis (Wegovy) Head-to-head comparison: Metformin vs
It makes your face look less full & more gaunt
DSIP is not an authorised UK treatment for insomnia, narcolepsy, withdrawal, pain or another medical condition
Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes
Patients who have been receiving compounded semaglutide through Hims should ask directly about the current pharmacy fulfilling their prescription and its regulatory status, particularly given the platforms transition toward branded medications following the March 2026 Novo Nordisk deal
